ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Amanda Hanson, Christopher J. Harvey|PLoS ONE|2020

Cited by 40